Current Report Filing (8-k)
06 January 2018 - 8:07AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT TO SECTION 13 OR 15(D)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): January 2, 2018
Tetraphase Pharmaceuticals, Inc.
(Exact name of registrant as specified in charter)
|
|
|
|
|
Delaware
|
|
001-35837
|
|
20-5276217
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
|
|
|
480 Arsenal Way
Watertown, Massachusetts
|
|
02472
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrants telephone number, including area code:
(617) 715-3600
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form
8-K
filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions (
see
General Instruction A.2. below):
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule
14a-12
under the Exchange Act (17
CFR 240.14a-12)
|
☐
|
Pre-commencement
communications pursuant to Rule
14d-2(b)
under the Exchange Act (17 CFR
240.14d-2(b))
|
☐
|
Pre-commencement
communications pursuant to Rule
13e-4(c)
under the Exchange Act (17 CFR
240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth company as
defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule
12b-2
of the Securities Exchange Act of 1934
(§240.12b-2
of this chapter).
Emerging growth company ☐
If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange
Act. ☐
On January 2, 2018, Tetraphase Pharmaceuticals, Inc. (the
Company) announced that it had completed its submission of a New Drug Application (the NDA) for intravenous (IV) eravacycline for the treatment of complicated intra-abdominal infections (cIAI). The NDA
submission was supported by data from the Companys phase 3 clinical trial known as IGNITE4 evaluating the efficacy and safety of twice-daily IV eravacycline compared to meropenem for the treatment of patients with cIAI and by data from the
Companys phase 3 clinical trial known as IGNITE1 evaluating the efficacy and safety of twice-daily IV eravacycline compared to ertapenem for the treatment of patients with cIAI.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
By:
|
|
/s/ Maria D. Stahl
|
Date: January 5, 2018
|
|
|
|
|
|
Maria D. Stahl
|
|
|
|
|
|
|
Senior Vice President, General Counsel
|
Tetraphase Pharmaceuticals (NASDAQ:TTPH)
Historical Stock Chart
From Apr 2024 to May 2024
Tetraphase Pharmaceuticals (NASDAQ:TTPH)
Historical Stock Chart
From May 2023 to May 2024
Real-Time news about Tetraphase Pharmaceuticals Inc (NASDAQ): 0 recent articles
More Tetraphase Pharmaceuticals Inc News Articles